glp 1 agonist therapy GLP-1 Agonists: A Comprehensive Overview Potential Use of GLP-1 and

Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs

[DOI] [PubMed] [Google Scholar] 26

These data indicate that d-allulose significantly suppressed glucose production in HFD-fed mice with insulin resistance

Recent research has raised significant concerns about accelerated bone density loss in GLP-1 users

Accordingly, the bulk of the clinical evidence of the effects of the drug class on HF have been collected in the placebo-controlled CVOTs in people with type 2 diabetes and established CVD or CVD risk (Table 1) (Pfeffer et al., 2015